A New Approach to PSP Research: Understanding the PSP Trial Platform

Progressive supranuclear palsy (PSP) research is taking a new approach with the launch of the PSP Trial Platform, a clinical trial designed to evaluate multiple potential treatments within one ongoing research framework.

The enrollment of the platform’s first participant marks an important milestone for PSP research. But what makes this study particularly noteworthy is not simply that a new clinical trial has begun. It is the way the trial is designed.

What is a platform trial?

Traditional clinical trials generally evaluate one potential treatment at a time. A platform trial allows researchers to study multiple treatments within a shared trial structure.

As research progresses, treatments may be added to or removed from the platform based on emerging evidence. This approach can make it possible to evaluate potential therapies more efficiently while using common study procedures and infrastructure.

Platform trials can also reduce the number of people assigned to a placebo by allowing multiple treatment arms to share a single placebo group.

For a rare disease such as PSP, where the number of people who may be eligible to participate in clinical research is limited, finding more efficient ways to conduct trials can be especially important.

Why this matters for PSP research

The PSP Trial Platform represents a collaborative effort to accelerate the study of potential treatments for PSP while also generating information that may contribute to a broader understanding of the disease.

Platform trials have the potential to reduce duplication between individual studies, make better use of available research infrastructure and allow researchers to adapt as new treatment candidates emerge.

The approach also reflects a larger shift in rare disease research toward trial designs that can make the most of every participant, every research site and every piece of data collected.

An important research milestone

The launch of the PSP Trial Platform is an encouraging development for the PSP community and for researchers working toward better treatments.

The trial has already met its current enrollment goals. The FTD Disorders Registry is sharing this update to help our community stay informed about developments in PSP research, rather than to recruit additional participants for the study.

As research continues to evolve, new study designs like the PSP Trial Platform may help researchers explore potential treatments more efficiently and build knowledge that can inform future PSP research.

With current enrollment goals already met, this milestone offers an opportunity to look at how new trial designs may help move PSP research forward. People with PSP, care partners, and family members can also support the broader research community by joining the FTD Disorders Registry, where participants can stay connected to research and help build the knowledge needed for future studies.

To learn more about PSP, visit AFTD’s Progressive Supranuclear Palsy page.